Join free
For vendorsSign inSign up free
← Back to Blog
Research Roundup7 min read

EloraTZP Phase 2 Results: 23.3% Weight Loss With Eloralintide + GLP-2T in T2D

By , co-founder & editorial lead

Quick referenceEloralintide
View live prices & vendors

The Number That Matters Up Front

At 48 weeks, adults with overweight or obesity and type 2 diabetes (T2D) receiving the highest dose of EloraTZP — eloralintide 9 mg plus GLP-2T 15 mg — lost a mean 23.3% of body weight, equivalent to about 54.1 lbs, according to Phase 2b results presented at the EASD 2026 Annual Meeting in Milan. That compares with 14.8% for GLP-2T 15 mg alone and 11.1% for eloralintide 9 mg alone in the same trial. All four EloraTZP dose combinations beat placebo (−3.0%) on the primary endpoint (EASD news release via EurekAlert). EloraTZP is investigational, not approved, and these are conference data not yet peer-reviewed.

This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions.

What EloraTZP Actually Is: A Third Appetite Axis Stacked on an Incretin Backbone

The pathway logic is why this readout matters beyond the headline number. GLP-2T already targets two pathways — GIP and GLP-1. Eloralintide adds a third: amylin, a peptide hormone released from pancreatic beta cells after eating that acts through its own distinct receptor to help regulate hunger and blood sugar. Lilly's framing is explicit: EloraTZP was developed to simultaneously activate three complementary nutrient-stimulated hormones — GIP, GLP-1, and amylin — each acting through its own receptor.

This three-pathway strategy is not unique to Lilly. Novo Nordisk is pursuing an analogous approach with CagriSema, which stacks cagrilintide (an amylin analogue) onto GLP-1S (a GLP-1 agonist). At EASD, TIME reported that CagriSema produced 22.4% weight loss in people with overweight or obesity without T2D, and Novo has submitted a U.S. FDA approval request for that indication. Our existing coverage of the CagriSema REIMAGINE 5 vs GLP-2T head-to-head provides the direct competitive backdrop: in a T2D population, CagriSema produced 12.4% weight loss versus 9.1% with GLP-2T at 60 weeks in that trial — a different study design, population, and duration, making direct cross-trial comparison unreliable.

The trial behind the new data was a 48-week, randomized, double-blind, placebo-controlled study of 367 adults with obesity or overweight and T2D in the US and Argentina, randomized across 10 treatment groups (Medscape). For compound-level background, see the site's eloralintide explainer; this article covers the first major efficacy readout of the combination rather than repeating the compound overview.

The emerging pattern: stacking amylin on an incretin backbone produces meaningfully more weight loss than the incretin alone, at least in Phase 2. Whether that translates into approved therapies depends on Phase 3 data that do not yet exist.

Full Dose-Response Table

Regimen Mean Weight Loss (48 wk) Absolute Loss A1c Reduction
Elora 9 mg + TZP 15 mg −23.3% −54.1 lbs −2.9 pp
Elora 6 mg + TZP 10 mg −19.9% −46.2 lbs −2.6 pp
Elora 6 mg + TZP 5 mg −19.4% −45.1 lbs −2.7 pp
Elora 3 mg + TZP 5 mg −13.2% −30.7 lbs −2.2 pp
TZP 15 mg alone −14.8% −34.4 lbs −2.4 pp
Elora 9 mg alone −11.1% −25.8 lbs −1.3 pp
Elora 6 mg alone −12.3% −28.6 lbs −1.4 pp
Elora 3 mg alone −8.2% −19.1 lbs −1.1 pp
Placebo −3.0% −7.0 lbs −0.3 pp

Source: EASD news release via EurekAlert, September 30, 2026 and Lilly press release via PR Newswire, September 30, 2026; efficacy estimand (assumes all participants remained on assigned intervention). Baseline mean weight 105.4 kg; baseline mean A1c 8.1%.

Note that A1c reductions for all four EloraTZP combinations (2.2–2.9 percentage points) were comparable to GLP-2T 15 mg alone (2.4 pp). The incremental glycemic gain appears modest even as the weight-loss gain is substantial.

Glycemia: Near-Universal A1c Control

While the weight-loss headline gets attention, the glycemic data are striking for people with T2D. Between 90% and 100% of participants receiving combination regimens achieved an A1c below 7% at week 48, and up to 77% achieved A1c below 5.7%, corresponding to normoglycemia. For context, mean baseline A1c was 8.1% — a population with meaningful hyperglycemia. These are trial-population rates under controlled conditions, not real-world outcomes.

For readers following how aggressive weight targets are getting across the investigational pipeline, compare these results with the site's coverage of the mazdutide Phase 2 readout and the survodutide SYNCHRONIZE Phase 3 results — noting that those trials enrolled different populations, which matters for cross-trial interpretation.

The Tolerability Ledger: What the Headlines Leave Out

The side-effect profile is the most important caveat in the readout and deserves precise reporting rather than a generic mention.

At the highest combination dose (eloralintide 3/6/9 mg + GLP-2T 15 mg):

  • Nausea: 48.6% vs 25.7% with GLP-2T alone
  • Vomiting: 24.3% vs 11.4%
  • Diarrhea: 29.7% vs 22.9%
  • Fatigue: 24.3% vs 14.3%

Events were generally mild or moderate and occurred primarily during dose escalation. One death occurred during the study — a motor vehicle accident judged unrelated to treatment (Medscape).

Discontinuation due to adverse events: 10.8%–27.0% with EloraTZP combinations vs 2.9% with GLP-2T alone (Lilly press release). The independent analysis from ConscienHealth flagged the 27% discontinuation rate at the highest dose as a meaningful tolerability signal, noting it contrasts sharply with the 4% discontinuation rate seen with petrelintide, a different amylin agonist reported at the same meeting.

There is a possible mitigation: the trial also tested a sequential strategy in which GLP-2T was escalated to 15 mg before eloralintide was added at week 24. In the sequential arm, nausea, fatigue, and vomiting rates were 27.8%, 13.9%, and 13.9% — much closer to GLP-2T alone (25.7%, 14.3%, 11.4%). Lead investigator Liana K. Billings, MD, described this as a "really nice illustration" of how sequencing could reduce the side-effect burden of simultaneous escalation. Lilly has said Phase 3 will use an optimized dose-escalation schedule (Medscape).

The important caveat from independent commentator Anna Solini, MD, PhD (University of Pisa): the combination arms in this Phase 2b trial contained fewer than 100 participants each, whereas some comparator trials included several hundred. Solini urged "very, very" cautious interpretation of the findings, particularly indirect comparisons with other obesity trials, and noted GLP-2T was likely the driving force behind the magnitude of weight loss.

The Delivery Caveat and the Phase 3 Timeline

A detail that matters for what patients could eventually receive: in this Phase 2b study, eloralintide and GLP-2T were administered as two separate injections. The single co-formulated product that would be practical for patients does not yet exist in a Phase 3-ready form. Lilly plans to initiate Phase 3 studies of a co-formulated EloraTZP product by the end of 2026 with an optimized dose-escalation schedule (EASD news release via EurekAlert). No regulatory filing for EloraTZP has been announced; Phase 3 initiation is not approval.

Eloralintide as a monotherapy is already in Phase 3 obesity trials — experience that helps Lilly on manufacturing and regulatory familiarity, but the combination product's Phase 3 path is separate and has not started.

Evidence Limits and What Comes Next

Several boundaries constrain interpretation:

  1. Phase 2b, not Phase 3. Combination-group sizes were under 100 participants each. Phase 3 with larger populations may reveal different tolerability and efficacy profiles.
  2. T2D population only. Results apply to adults with obesity/overweight and type 2 diabetes. Outcomes in people without T2D are unknown for this combination.
  3. Conference presentation, not peer review. Full findings have not yet been published in a peer-reviewed journal.
  4. Efficacy estimand. The 23.3% figure assumes all randomized participants remained on their assigned intervention — a modeled estimate, not a completers-only observed result.
  5. Funded by Eli Lilly. The study was industry-sponsored; lead investigator Billings has disclosed consulting relationships with multiple companies including Lilly and Novo Nordisk.

ConscienHealth's independent read notes that the 23.3% figure exceeds the 20.8% weight loss reported at 80 weeks with GLP-3R in TRIUMPH-2 (another T2D-and-obesity study) — while cautioning that cross-trial comparisons are unreliable given different populations, doses, durations, and designs.

Continue your research

Sources

Keep researching